Suppression of the mouse double minute 4 gene causes changes in cell cycle control in a human mesothelial cell line responsive to ultraviolet radiation exposure

Environmental and Molecular Mutagenesis

Volumn 50, Issue 9, 2009, Pages 753-759

  Bunderson Schelvan, Melisa ^a   Erbe, Amy K ^b   Schwanke, Corbin ^a   Pershouse, Mark A ^a  

^a UNIVERSITY OF MONTANA   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Apoptosis; Cell cycle regulation; p53 tumor suppressor

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1A; PROTEIN BAX; PROTEIN MDMX; PROTEIN P21; PROTEIN P53; SHORT HAIRPIN RNA;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CELL GROWTH; CELL LINE; CELL SURVIVAL; CONTROLLED STUDY; GENE ACTIVITY; GENE FUNCTION; GENE MUTATION; GENE REPRESSION; HUMAN; HUMAN CELL; MESOTHELIOMA; MESOTHELIUM CELL; MET5A CELL; PROTEIN FUNCTION; PROTEIN TARGETING; RADIATION EXPOSURE; RADIATION RESPONSE; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE; ULTRAVIOLET RADIATION; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; CELL CYCLE; CELL LINE; EPITHELIUM; GENE SILENCING; GENES, P53; HUMANS; MICE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTO-ONCOGENE PROTEINS; UBIQUITIN-PROTEIN LIGASES; ULTRAVIOLET RAYS;

EID: 73249120364     PISSN: 08936692     EISSN: 10982280     Source Type: Journal    
DOI: 10.1002/em.20498     Document Type: Article

References (26)

1. Barlow C, Brown KD, Deng CX, Tagle DA, Wynshaw-Boris A. 1997. Atm selectively regulates distinct TP53-dependent cell-cycle checkpoint and apoptotic pathways. Nat Genet 17:453-456.
2. Brooks CL, Gu W. 2006. TP53 ubiquitination. MDM2 and beyond. Mol Cell 21:307-315.
3. Chavez-Reyes A, Parant JM, Amelse LL, Montes de Oca Luna R, Korsmeye SJ, Lozano G. 2003. Switching mechanisms of cell death in MDM2- and MDM4-null mice by deletion of TP53 downstream targets. Cancer Res 63:8664-8669.
4. Danovi D, Meulmeester E, Pasini D, Migliorini D, Capra M, Frenk R, de Graaf P, Francoz S, Gasparini P, Gobbi A, Helin K, Pelicci PG, Jochemsen AG, Marine JC. 2004. Amplification of Mdmx (or MDM4) directly contributes to tumor formation by inhibiting TP53 tumor suppressor activity. Mol Cell Biol 24:5835-5843.
5. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. 1993. WAF1 a potential mediator of TP53 tumor suppression. Cell 75:817-825.
6. Francoz S, Froment P, Bogaerts S, De Clerq S, Maetens M, Doumont G, Bellefroid E, Marine JC. 2006. MDM4 and MDM2 cooperated to inhibit TP53 activity in proliferating and quiescent cells in vivo. Proc Natl Acad Sci USA 103:3232-3237.
7. 1 cyclin-dependent kinases. Cell 75:805-816.
8. CDKN1A in cells surviving UV-irradiation. DNA Repair 4:1457-1462.
9. Jin Y, Zeng SX, Sun XX, Lee H, Blattner C, Xiao Z, Lu H. 2008. MDMX promotes proteasomal turnover of p21 at G1 and early S phases independently of, but in cooperation with, MDM2. Mol Cell Biol 28:1218-1229.
10. Kashatus D, Cogswell P, Baldwin AS. 2006. Expression of the Bcl-3 proto-oncogene suppresses TP53 activation. Genes Dev 20:225-235.
11. Maddika S, Ande SR, Panigrahi S, Paranjothy T, Weglarczyk K, Zuse A, Eshraghi M, Manda KD, Wiechec E, Los M. 2007. Cell survival, cell death and cell cycle pathways are interconnected: Implications for cancer therapy. Drug Resist Updat 10:13-29.
12. Mancini F, Gentiletti F, D'Angelo M, Giglio S, Nanni S, D'Angelo C, Farsetti A, Citro G, Sacchi A, Pontecorvi A, Moretti F. MDM4 (MDMX) overexpression enhances stabilization of stress-induced TP53 and promotes apoptosis. 2004. J Biol Chem 279:8169-8180.
13. Marine JC, Jochemsen AG. 2005. Mdmx as an essential regulator of TP53 activity. Biochem Biophys Res Commun 331:750-760.
14. Michael D, Oren M. 2002. The TP53 and MDM2 families in cancer. Curr Opin Genet Dev 12:53-59.
15. Miyashita T, Reed JC. 1995. Tumor suppressor TP53 is a direct transcriptional activator of the human bax gene. Cell 80:293-299.
16. Momand J, Wu HH, Dasgupta G. 2000. MDM2-master regulator of the TP53 tumor suppressor protein. Gene 242:15-29.
17. kip1: A target for tumor therapies? Cell Div 9:2-13.
18. Parant J, Chavez-Reyes A, Little NA, Yan W, Reinke V, Jochemsen AG, Lozano G. 2001. Rescue of embryonic lethality in Mdm4-null mice by loss of TrTP53 suggests a nonoverlapping pathway with MDM2 to regulate TP53. Nat Genet 29:92-95.
19. Pereg Y, Shkedy D, de Graaf P, Meulmeester E, Edelson-Averbukh M, Salek M, Biton S, Teunisse AF, Lehmann WD, Jochemsen AG, Shiloh Y. 2005. Phosphorylation of Hdmx mediates its Hdm2-and ATM-dependent degradation in response to DNA damage. Proc Natl Acad Sci USA 102:5056-5061.
20. Prodosmo A, Giglio S, Moretti S, Mancini F, Barbi F, Avenia N, Di Conza G, Schünemann HJ, Pistola L, Ludovini V, Sacchi A, Pontecorvi A, Puxeddu E, Moretti F. 2008. Analysis of human MDM4 variants in papillary thyroid carcinomas reveals new potential markers of cancer properties. J Mol Med 86:585-596.
21. Puhalla H, Wrba F, Kandioler D, Lehnert M, Huynh A, Gruenberger T, Tamandl D, Filipits M. 2007. Expression of CDKN1A(Waf1/Cip1), p57(Kip2) and HER2/new in patients with gallbladder cancer. Anticancer Res 27:1679-1684.
22. Qin JZ, Chaturvedi V, Denning MF, Bacon P, Panella J, Choubey D, Nickoloff BJ. 2002. Regulation of apoptosis by p53 in UV-irradiated human epidermis, psoriatic plaques and senescent keratinocytes. Oncogene 21:2991-3002.
23. Riemenschneider MJ, Knobbe CB, Reifenberger G. 2003. Refined mapping of 1q32 amplicons in malignant gliomas confirms MDM4 as the main amplification target. Int J Cancer 104:752-757.
24. Stad R, Ramos YFM, Little N, Grivell S, Attema J, van Der Eb AJ, Jochemsen AG. 2000. Hdmx stabilizes MDM2 and TP53. J Biol Chem 275:28039-28044.
25. Steinman HA, Sluss HK, Sands AT, Pihan G, Jones SN. 2004. Absence of CDKN1A(Cip1/waf1) partially rescues MDM4 loss and uncovers an antiproliferative effect of MDM4 on cell growth. Oncogene 23:303-306.
26. Veerakumarasivam A, Scott HE, Chin SF, Warren A, Wallard MJ, Grimmer D, Ichimura K, Caldas C, Collins VP, Neal DE, Kelly JD. 2008. High-resolution array-based comparative genomic hybridization of bladder cancers identifies mouse double minute 4 (MDM4) as an amplification target exclusive of MDM2 and TP53. Clin Cancer Res 14:2527-2534.